Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Strony

Showing results (21-30 of 50) with videos related to

Pageof 5
Sort By:
The Journal of the American Academy of Orthopaedic Surgeons|May 28, 2021
Oral Ketorolac as an Adjuvant Agent for Postoperative Pain Control After Arthroscopic Rotator Cuff Repair: A Prospective, Randomized, Controlled StudyLakshmanan Sivasundaram, Sunita Mengers, Nikunj N Trivedi, et al.
American Heart Journal|August 25, 2009
Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trialDavid A Morrow, Benjamin M Scirica, Keith A A Fox, et al.
The New England Journal of Medicine|November 15, 2021
Milvexian for the Prevention of Venous ThromboembolismJeffrey I Weitz, John Strony, Walter Ageno, et al.
Journal of Thrombosis and Haemostasis : JTH|September 19, 2019
Randomized phase 2 trial comparing JNJ-9375, a thrombin-directed antibody, with apixaban for prevention of venous thrombosisJeffrey I Weitz, Annelise Segers, Gary Raskob, et al.
Circulation. Cardiovascular Interventions|May 31, 2015
Magnitude of troponin elevation and long-term clinical outcomes in acute coronary syndrome patients treated with and without revascularizationAkshay Bagai, Zhen Huang, Yuliya Lokhnygina, et al.
American Heart Journal|December 9, 2008
Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromesChristopher P Cannon, Robert P Giugliano, Michael A Blazing, et al.
Journal of the American College of Cardiology|February 2, 2002
Eptifibatide and low-dose tissue plasminogen activator in acute myocardial infarction: the integrilin and low-dose thrombolysis in acute myocardial infarction (INTRO AMI) trialSorin J Brener, Uwe Zeymer, A A Jennifer Adgey, et al.
Lancet (London, England)|March 17, 2009
Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II studyRichard C Becker, David J Moliterno, Lisa K Jennings, et al.
Journal of the American Heart Association|December 17, 2015
Efficacy and Safety of Vorapaxar in Non-ST-Segment Elevation Acute Coronary Syndrome Patients Undergoing Noncardiac SurgerySean van Diepen, Pierluigi Tricoci, Mohua Podder, et al.
Journal of the American Heart Association|December 12, 2018
Stroke Outcomes With Vorapaxar Versus Placebo in Patients With Acute Coronary Syndromes: Insights From the TRACER TrialLeo Ungar, Robert M Clare, Fatima Rodriguez, et al.
Pageof 5

Showing results (21-30 of 50) with videos related to

Sort By:
Pageof 5
The Journal of the American Academy of Orthopaedic Surgeons|May 28, 2021
Oral Ketorolac as an Adjuvant Agent for Postoperative Pain Control After Arthroscopic Rotator Cuff Repair: A Prospective, Randomized, Controlled StudyLakshmanan Sivasundaram, Sunita Mengers, Nikunj N Trivedi, et al.
American Heart Journal|August 25, 2009
Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trialDavid A Morrow, Benjamin M Scirica, Keith A A Fox, et al.
The New England Journal of Medicine|November 15, 2021
Milvexian for the Prevention of Venous ThromboembolismJeffrey I Weitz, John Strony, Walter Ageno, et al.
Journal of Thrombosis and Haemostasis : JTH|September 19, 2019
Randomized phase 2 trial comparing JNJ-9375, a thrombin-directed antibody, with apixaban for prevention of venous thrombosisJeffrey I Weitz, Annelise Segers, Gary Raskob, et al.
Circulation. Cardiovascular Interventions|May 31, 2015
Magnitude of troponin elevation and long-term clinical outcomes in acute coronary syndrome patients treated with and without revascularizationAkshay Bagai, Zhen Huang, Yuliya Lokhnygina, et al.
American Heart Journal|December 9, 2008
Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromesChristopher P Cannon, Robert P Giugliano, Michael A Blazing, et al.
Journal of the American College of Cardiology|February 2, 2002
Eptifibatide and low-dose tissue plasminogen activator in acute myocardial infarction: the integrilin and low-dose thrombolysis in acute myocardial infarction (INTRO AMI) trialSorin J Brener, Uwe Zeymer, A A Jennifer Adgey, et al.
Lancet (London, England)|March 17, 2009
Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II studyRichard C Becker, David J Moliterno, Lisa K Jennings, et al.
Journal of the American Heart Association|December 17, 2015
Efficacy and Safety of Vorapaxar in Non-ST-Segment Elevation Acute Coronary Syndrome Patients Undergoing Noncardiac SurgerySean van Diepen, Pierluigi Tricoci, Mohua Podder, et al.
Journal of the American Heart Association|December 12, 2018
Stroke Outcomes With Vorapaxar Versus Placebo in Patients With Acute Coronary Syndromes: Insights From the TRACER TrialLeo Ungar, Robert M Clare, Fatima Rodriguez, et al.
Pageof 5